Expert panel suggests moving Covaxin out of 'clinical trial mode'

On Wednesday, the Drugs Controller General of India (DCGI) recommended that Bharat Biotech's indigenously produced Covaxin be granted emergency use authorization, with the requirement that the vaccine is administered in 'clinical trial mode' removed.

If the expert panel's advice is approved by the country's top medicines regulator, beneficiaries will not be asked to sign a consent form to receive the indigenous coronavirus vaccine. Previously, the vaccine could only be used in an emergency in a clinical trial environment. According to the SEC, the decision was reached after reviewing interim phase three trial data for the vaccine produced by Bharat Biotech in collaboration with the ICMR.